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Insulin Degludec, The new Generation Basal Insulin  
or Just another Basal Insulin?
Sami n. nasrallah and L. Raymond Reynolds
University of Kentucky. Corresponding author email: sami.nasrallah@uky.edu
Abstract: The advances in recombinant DNA technology have led to an improvement in the properties of currently available long-
acting insulin analogs. Insulin degludec, a new generation ultra-long-acting basal insulin, currently in phase 3 clinical trials, has a 
promising future in clinical use. When compared to its rival basal insulin analogs, a longer duration of action and lower incidence of 
hypoglycemic events in both type 1 and type 2 diabetic patients has been demonstrated.1,2 Its unique mechanism of action is based on 
multihexamer formation after subcutaneous injection. This reportedly allows for less pharmacodynamic variability and within-subject 
variability than currently available insulin analogs, and a duration of action that is over 24 hours.3 The lack of proof of carcinogenicity 
with insulin degludec is yet another factor that would be taken into consideration when choosing the optimal basal insulin for a diabetic 
individual.4 A formulation of insulin degludec with insulin aspart, Insulin degludec 70%/aspart 30%, may permit improved flexibly of 
dosing without compromising glycemic control or safety.5
Keywords: insulin degludec, basal insulin, insulin analogs, insulin degludec70%/aspart30%, long-acting insulin analogs
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Introduction
Pancreatic beta cells release insulin continuously 
between meals at a near constant rate and in the fast-
ing state. This basal insulin secretion acts to restrain 
the release of glucose from the liver and free fatty 
acids from the adipose tissue in order to prevent 
hyperglycemia and ketosis. The development of insu-
lin analogs, in effort to produce safer insulin formula-
tions that would closely mimic the basal and mealtime 
components of endogenous insulin secretion, allowed 
for more flexible treatment regimens with a lower 
risk of development of hypoglycemia. Insulin ana-
logs, created via recombinant DNA technology, are 
modified versions of human insulin that primarily 
alter the duration of absorption of the molecule. An 
improvement in the properties of currently available 
long-acting insulin analogs has been achieved with 
the new generation long-acting basal insulin analog, 
insulin degludec. Clinical trials have demonstrated 
a longer duration of action and lower incidence of 
hypoglycemic events in both type 1 and type 2 dia-
betic patients using insulin degludec.1,2 This article 
reviews  currently available information about insu-
lin degludec, in comparison to the other basal insulin 
analogs (Table 1 and Fig. 1).
Mechanism of Action, Metabolism  
and Pharmacokinetic Profile
Insulin degludec is a neutral, soluble ultra-long-acting 
insulin that forms large multihexamer assemblies at 
physiological pH following subcutaneous injection. 
Its molecular structure is similar to the human insulin 
amino acid sequence, apart from deletion of  Threonine 
at position B30 and the addition of a 16-carbon fatty 
diacid attached to Lysine at position B29 via a glutamic 
acid spacer (Fig. 1). This  conformation allows insulin 
degludec to exist as  dihexamers in  solution which form 
multihexamers after subcutaneous injection.3 Accord-
ing to the manufacturer, Novo Nordisk, the large 
molecular size allows for continuous slow release of 
degludec monomers with reportedly less pharmacody-
namic variability and within-subject variability than 
currently available insulin analogs, and a duration of 
action that is over 24 hours. Its metabolism is mainly 
via the kidneys. The contribution of renal metabolism 
is enhanced as exogenous insulin bypasses the liver.3,6
A study involving 12 type 1 diabetic subjects has 
shown that insulin degludec had a half life longer than 
24 hours and was found to be detectable in the circu-
lation for at least 96 hours after injection; however, 
it is unknown whether or not it is still biologically 
active at that time. Insulin receptor binding studies 
and in vitro studies have indicated that insulin deglu-
dec is comparable to human insulin in its low affinity 
for the human insulin-like growth factor-1 receptor, 
with a similar low mitogenic/metabolic potency ratio 
and, therefore, no proof of carcinogenicity.4,6–8
clinical studies
Phase 2 trials
Three phase 2 trials comparing insulin degludec with 
insulin glargine have been conducted. All were open-
label, randomized, parallel-group, treat-to-target  trials 
and had a duration of 16-weeks.
A trial including type 1 diabetes patients showed 
no differences in hemoglobin A1c, fasting plasma glu-
cose, and mean total daily dose between insulin deglu-
dec once a day with insulin glargine once a day, both 
combined with insulin aspart. There was a difference 
in the rate of confirmed hypoglycemia and especially 
confirmed nocturnal hypoglycemia between  insulin 
degludec once a day and insulin glargine once a day. 
Table 1. Comparison of insulin degludec and other insulin analogs. 
Basal insulin Onset peak Duration comments
nPH 1–2 hours 4–8 hours 8–12 hours Greatest risk for hypoglycemia
Glargine 30–60 minutes no peak 16–24 hours – Greatest potential for weight gain. 
– Possible mitogenicity
Detemir 30–60 minutes no peak 16–24 hours May need twice daily injections.
Degludec 30–90 minutes no peak over 24 hours – Least risk of hypoglycemia 
– no mitogenicity
Degludec plus 5–15 minutes 30–60 minutes over 24 hours Same as degludec with advantage 
of added prandial coverage.
Abbreviation: nPH, neutral protamine hagedorn.
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The rates of overall and nocturnal  hypoglycemia of 
insulin degludec and insulin glargine and the risk 
reductions compared with glargine were 47.9 and 
66.2 events/patient-year (relative risk 0.72) and 5.1 
and 12.3 events/patient-year (relative risk 0.42), both 
in favor of insulin degludec once a day.1,9–11
A study among diabetes type 2 patients tested 
insulin degludec in either a once per day regimen or a 
three-times weekly regimen, compared against insu-
lin glargine. All efficacy outcome measures, including 
the mean weekly insulin dose, were similar compared 
with each other and compared with insulin glargine. 
This study among type 2 diabetes patients, found no 
significant differences in the rate of confirmed hypo-
glycemic events among degludec once a day, deglu-
dec three-times weekly, and insulin glargine once a 
day. Although hypoglycemic events occurred less 
with degludec once a day, they occurred more in the 
degludec three-times weekly treatment group.1,2,12 
Therefore, its manufacturer, Novo Nordisk, is seek-
ing FDA approval for once a day clinical use.
A third study investigated a Insulin degludec Plus 
co-formulation, comprising 70% insulin degludec and 
30% insulin aspart in type 2 diabetes patients dosed 
at dinnertime. There was no difference in hemoglobin 
A1c and fasting plasma glucose compared with insu-
lin glargine once a day.
Two outcome measures were in favor of Insulin 
degludec Plus compared with insulin glargine: Insulin 
degludec Plus had a 27 mg/dL lower mean 2-h post-
dinner plasma glucose and a 7 U/kg lower mean daily 
insulin dose. The rate of confirmed hypoglycemic 
events and nocturnal hypoglycemic events was low 
for both Insulin degludec Plus and insulin glargine, 
without significant differences between them.1,13,14 
This co formulation is a promising treatment option for 
initiating insulin therapy in subjects with type 2 dia-
betes inadequately controlled with oral anti- diabetic 
agents. The phase 2 trial also investigated the use of 
a second formulation of insulin degludec 55%/Aspart 
45%, which was associated with a twofold higher rate 
of confirmed, mostly nocturnal, hypoglycemia which 
discontinued its clinical development.13
In a proof-of-concept trial comparing  Insulin 
degludec/aspart with biphasic insulin aspart 30 (30% 
soluble, rapid-acting insulin aspart and 70% protamine-
bound insulin aspart), Insulin degludec/aspart was 
associated with a significantly lower fasting plasma 
glucose and a significantly lower rate of confirmed 
hypoglycemia than biphasic insulin aspart 30.15
Phase 3 studies
12 phase 3 trials are registered at www.ClinicalTrials.
gov aiming to assess the efficacy and safety of insulin 
degludec, including approximately 7,000 participants, 
and all studies have been completed. Preliminary 
results of the phase 3 trials showed that there were 
no differences in A1c between Insulin degludec once 
a day and Insulin glargine, although Insulin degludec 
was not non-inferior regarding A1c when adminis-
tered three-times weekly in patients with type 2 dia-
betes, resulting in discontinuation of the three-times 
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Figure 1. Molecular structure of long-acting insulin analogs: (A) insulin glargine, (B) insulin detemir, and (c) insulin degludec.
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weekly dosing option. In the once a day dosing option, 
a reduction in nocturnal hypoglycemia was seen in 
a 52-week trial, together with a significantly lower 
fasting plasma glucose level. In one study, insulin 
degludec given as basal-bolus treatment with insu-
lin aspart in people with type 2 diabetes, improved 
long-term glycemic control with significantly lower 
risk of overall and nocturnal hypoglycemia compared 
with insulin glargine. In patients with type 1 diabetes, 
Insulin degludec once a day reduced the risk of noc-
turnal hypoglycemia compared with Insulin glargine 
once a day.1,16 In another phase 3 trial, the efficacy 
and safety of Insulin degludec/aspart used once daily 
at any meal with insulin aspart at the remaining meals 
in type 1 diabetics, provided similar glycemic control 
to insulin detemir with mealtime insulin aspart. The 
Insulin degludec/aspart regimen was associated with 
significantly less nocturnal hypoglycemia, and had 
the added convenience of fewer daily injections than 
conventional basal-bolus therapy.17
safety
Insulin degludec used alone is associated with less 
pharmacodynamic and within-subject variability 
than insulin glargine, with a lower chance of induc-
ing hypoglycemia, in both type 1 and type 2 diabetic 
patients.2,9,18 The rates of hypoglycemia and noctur-
nal hypoglycemia, in insulin-naïve people with type 
2 diabetes, were similar between insulin degludec 
70%/insulin aspart 30% and insulin glargine. This 
lower risk of inducing hypoglycemia, in particular 
nocturnal hypoglycemia, might be a major factor in 
choosing a regimen to that targets optimal glycemic 
control, especially in patients with blunted hypogly-
cemic awareness.
In studies involving the binding affinity of insulin 
degludec to IGF-1 receptors, the affinity of insulin 
degludec for the human IGF-1 receptor was found 
to be low, with a molecular safety that is similar to 
human insulin. This has omitted any proof of carci-
nogenicity with insulin degludec, in comparison to 
concerns regarding possible metabolic and mitogenic 
potencies of insulin glargine.4
Efficacy
The continuous, slow, stable release of insulin deglu-
dec monomers provides a smooth and stable expo-
sure for more than 24 hours, with less variability and 
a more stable glucose-lowering effect than insulin 
glargine.9,19,20 Insulin degludec 70%/aspart 30% has 
the added advantage of a lower mean 2-h post-dinner 
plasma glucose increment and lower mean daily insu-
lin dose when compared to insulin glargine.1,13 In one 
trial, it was shown that insulin degludec can be dosed 
flexibly at any time of the day so that injection times 
can be changed from day to day without compromis-
ing glycemic control or safety compared to insulin 
glargine dosed at the same day.5
patient preference
Based on the long duration of action and lower events 
of hypoglycemia and unproven carcinogenicity, the 
main determinant of patient preference will probably 
be the cost of insulin degludec given once a day.
place in Therapy
Insulin degludec has a high potential for use as an 
ultra-long acting basal insulin in both the ambulatory 
and inpatient setting, with a more favorable profile 
compared to the other basal insulins currently in use. 
One possible disadvantage in its use in the hospi-
tal setting, due to its prolonged effect of more than 
24 hours, is the decreased ability to make day-to-day 
adjustments in the basal insulin dose, in order to opti-
mize blood sugar control. This potential risk may be 
more pronounced in patients with renal or hepatic 
impairment. The long acting analogs currently in use, 
glargine and detemir, both allow for adjustments on 
a daily basis or shorter period, in advent of hypogly-
cemia or hyperglycemia.8,13 However, newer clinical 
studies have shown that the soluble insulin combina-
tion of an ultra-long-acting basal insulin degludec and 
rapid-acting insulin, insulin aspart, provides fasting 
plasma glucose control with significantly less hypo-
glycemia compared to biphasic insulin aspart.21
Discussion
The introduction of insulin analogs has revolutionized 
glycemic control, through administration of basal and 
prandial insulin with or without “correction dose” 
insulin, which in turn approximates physiologic insu-
lin demand. Insulin Lispro was the first rapid acting 
insulin analog, created by inversion of the lysine of 
B29 and the proline of B28 of human insulin, caus-
ing a conformational change that results in a shift in 
the normal binding of the C-terminal  portion of the B 
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chain, which in turn reduces the formation of dimers 
and hexamers. In contrast, the concept behind insulin 
degludec, is multihexamer formation at the subcu-
taneous injection site which prolongs its duration of 
action. This mechanism of action differs from insulin 
degludec’s predecessors, insulin glargine, which was 
introduced in 2001, and insulin detemir (Table 1). 
Insulin glargine is produced by the substitution of 
glycine for asparagine at position A21 of the insulin 
molecule and by the addition of two arginine mol-
ecules at position B30 (Fig. 1). These changes lead 
to a shift in the isoelectric point toward a neutral 
pH, which results in an insulin molecule that is less 
soluble at the injection site and that precipitates in 
the subcutaneous tissue to form a depot from which 
insulin is slowly released.7,22 Insulin detemir is an 
acylated derivative of human insulin which binds to 
albumin through a fatty-acid chain attached to the 
lysine at residue B29, leading to a reduction in free 
detemir levels (Fig. 1).
In both type 1 and 2 diabetics, the main advan-
tage with the use of insulin glargine instead of neutral 
protamine hagedorn insulin “NPH”, has been a reduc-
tion in the risk of hypoglycemia, especially nocturnal 
hypoglycemia.22 In type 2 diabetics, insulin glargine 
is comparable with NPH insulin, insulin detemir and 
exenatide in reducing A1c levels. Disadvantages of 
insulin glargine include weight gain versus weight 
loss with GLP-1 agonists and more effective A1c 
reduction with biphasic insulins if insulin glargine 
is not combined with prandial coverage.23 A recent 
meta-analysis comparing the efficacy and safety of 
long-acting insulin analogs in patients with type 2 
diabetes failing on oral therapy, demonstrated that ini-
tiating long-acting insulin analogs seems to provide 
glycemic control similar to rapid-acting insulin ana-
logs or NPH insulin or glucagon-like peptide-1 ana-
logs and slightly inferior to biphasic insulin analogs 
with fewer side-effects.22,24 Insulin detemir has less 
variability in absorption than does NPH, a feature 
associated with a reduced risk of hypoglycemia which 
may contribute to less weight gain (Table 1). Insulin 
detemir appears to have a shorter time–action profile 
at lower doses, compared with insulin glargine, which 
may require twice-daily injections in persons with 
type 1 diabetes.22,25 A recent analyses suggested that 
there is no clinically relevant difference in efficacy or 
safety between insulin detemir and insulin glargine for 
 targeting  hyperglycemia. However, to achieve the same 
glycemic control insulin detemir was often injected 
twice-daily in a higher dose but with less weight gain, 
while insulin glargine was injected once-daily, with 
somewhat fewer injection site reactions. As with insu-
lin glargine, similar advantages with insulin detemir 
include lower incidence of hypoglycemia compared 
with NPH and biphasic insulins23 (Table 1).
With insulin degludec having less pharmacody-
namic and within-subject variability than insulin 
glargine and detemir, there is a reduced chance of 
inducing hypoglycemia, in both type 1 and type 2 
diabetic patients. Similar rates of hypoglycemia and 
nocturnal hypoglycemia, in insulin-naïve people with 
type 2 diabetes have been shown with insulin deglu-
dec 70%/insulin aspart 30% and insulin glargine.2,9,18
There have been concerns of the metabolic and 
mitogenic potencies of insulin glargine, due to IGF-1 
—receptor binding and demonstration of an increase in 
both IGF-1—receptor affinity and mitogenic potency 
in a cell-culture model that used human osteosarcoma 
cells. This was implicated in the possible development 
of mammary, ovarian, and bone tumors in addition 
to the development of diabetic retinopathy. Due to 
these suspicions, it has been considered unwise to use 
insulin glargine in pregnancy.22,25 Newer data, from a 
large population-based follow-up study, showed that 
insulin glargine and users of other insulin analogs 
had a lower risk of cancer in general than those using 
human insulin; however, an increased risk of breast 
cancer was seen in users of insulin glargine in com-
parison with users of human insulin.26 In a more recent 
cohort study involving only type 2 diabetic patients, 
the previous findings of an increased risk of cancer 
with insulin glargine compared with human insulin 
was not confirmed, and an increased risk of all-cause 
death with human insulin was found when compared 
with insulin glargine.27 With insulin degludec, since 
its affinity for the human IGF-1 receptor is low, the 
molecular safety is similar to human insulin, with no 
proof of carcinogenicity (Table 1).4
conclusions
The new ultra-long basal insulin degludec , which is 
currently still undergoing phase 3 trials, may be an 
attractive therapeutic alternative to the other basal 
insulins, due to less pharmacodynamic  variability, 
a longer duration of action, less potential for 
nasrallah and Reynolds
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 hypoglycemic events and lower theoretical mitogenic 
potential. Its developer, Novo Nordisk, has filed for 
regulatory approval but at this writing it still awaits 
approval in Europe and the US for clinical use.
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